通过阻断IL-33/IL1RL1通路,对瘤细胞和免疫微环境进行双重向
Denggang Fu1,2, Hua Jiang1,2, Alan Long3
1Department of Microbiology and Immunology and Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
Nature communications
|July 14, 2025
概括
白血病干细胞 (LSC) 通过IL-33/IL1RL1循环驱动急性髓性白血病 (AML). 向IL1RL1为AML提供了一种新的免疫疗法方法,既针对癌细胞,也针对它们的支持性微环境.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 白血病干细胞 (LSCs) 是白血病发展和治疗耐药性的关键驱动因素.
- 骨髓和免疫微环境显著影响LSC行为.
- 了解LSC免疫相互作用是开发有效免疫疗法的关键.
研究的目的:
- 研究IL-33/IL1RL1轴在急性髓性白血病 (AML) 发病过程中的作用.
- 通过分析LSC-免疫相互作用来确定AML的新型治疗点.
- 探索针对IL1RL1进行AML免疫治疗的潜力.
主要方法:
- 对公共数据集和患者样本的分析.
- 调查LSC白血病发生中的IL-33/IL1RL1自身隐性循环.
- 评估IL1RL1作为AML的治疗点.
主要成果:
- 升高的IL1RL1表达与AML的预后不佳和治疗抵抗有关.
- 一个压力诱导的IL-33/IL1RL1自克林循环驱动LSC的启动和维护.
- 这种信号通路创造了一个免疫抑制的微环境.
结论:
- IL1RL1是AML的一个有前途的治疗点.
- 向IL1RL1,可能通过T细胞参与的两种特异性抗体,代表了一种新的免疫治疗策略.
- 同时针对LSC和免疫微环境提供了一种对抗AML的双重方法.
更多相关视频
相关概念视频
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


